Australian preventative and personalised health platform provider Everlab has raised AU$65m in Series A funding, which the company says will be used to strengthen its clinical and technology infrastructure and accelerate its global rollout.
The oversubscribed round was led by Airtree Ventures (AU), with participation from global investors including Plural (EU) and existing investors Left Lane Capital (US) and b2venture (EU), alongside angel investors including Australian Test captain Pat Cummins.
Everlab cofounder and CEO Marc Hermann said the round marked the company’s evolution into “a complete care platform, transforming the primary care system built to treat illness into one built to prevent it.”
Everlab’s digital app organises diagnostics, doctors, specialists, prescriptions and continuous AI care in one place, with the aim of providing patients with a longitudinal view of their health.
The platform integrates with more than 1,850 health provider locations, 180 active clinicians and 30 wearable devices and processes over 200,000 health reports per month.
“The existing system is fragmented, handing patients between providers and hoping the information follows,” Mr Hermann said.
“We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next – from targeted screenings to personalised health plans – helping more people live longer, healthier lives.”
The company pointed to platform data showing a total of over 21 million biomarker test results, which had resulted in more than 25 per cent of members being notified of findings that were not identified through the existing healthcare system.
Everlab chief medical officer Dr Steven Lu said the company’s patient base reflected the broader Australian population and noted “earning their trust to hold decades of their health data is the foundation everything else runs on.”
“Our goal is to cut a new path for primary care globally, proving that deep patient engagement and first-class preventative care don’t just improve outcomes – it reduces the lifetime cost of care for everyone.”
The company said the raise marked its move into the $10 trillion global consumer healthcare market, starting with the UK, with the funding targeted at strengthening clinical and technology infrastructure and accelerating global rollout.
Airtree partner John Henderson said “the more time we spent with the Everlab team, the more convinced we became that they’re building a generational health business.”
“With a world-class product and growing at a pace we rarely see, they’re already the leader in Australia and we’re backing them to do the same globally.”
Plural partner Carina Namih said, “every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins.”
“Everlab is building the layer above both – the system that interprets and coordinates your health data over time rather than capturing a single transaction,” Ms Namih said.
“The fact that they’ve already proven their model operationally in Australia, at scale, is what convinced me this is the version that genuinely works.”
Founded in Melbourne in 2023, Everlab has completed 40,000+ consultations supporting 20,000 individual patients and major corporate partners – including Boston Consulting Group, BHP and Bain & Company.
Add Comment